Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01790243
Other study ID # CL0006-01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 20, 2011
Est. completion date November 1, 2018

Study information

Verified date May 2020
Source C. R. Bard
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of the LEVANT 2 Extended Follow-up Post-Approval Study (PAS 1) is to evaluate the long-term performance of the Lutonix Drug Coated Balloon (DCB) versus Percutaneous Transluminal Balloon Angioplasty (PTA) in the treatment of stenosis or occlusion of the femoropopliteal arteries.


Recruitment information / eligibility

Status Completed
Enrollment 1189
Est. completion date November 1, 2018
Est. primary completion date November 27, 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Clinical Inclusion Criteria:

1. Male or non-pregnant female =18 years of age;

2. Rutherford Clinical Category 2-4;

3. Patient is willing to provide informed consent, is geographically stable and comply with the required follow up visits, testing schedule and medication regimen;

Angiographic Lesion Inclusion Criteria:

4. Length =15 cm;

5. Up to two focal lesions or segments within the designated 15 cm length of vessel may be treated (e.g. two discrete segments, separated by several cm, but both falling within a composite length of <15 cm);

6. =70% stenosis by visual estimate;

7. Lesion location starts =1 cm below the common femoral bifurcation and terminates distally =2 cm below the tibial plateau AND =1 cm above the origin of the TP trunk;

8. De novo lesion(s) or non-stented restenotic lesion(s) >90 days from prior angioplasty procedure;

9. Lesion is located at least 3 cm from any stent, if target vessel was previously stented;

10. Target vessel diameter between =4 and =6 mm and able to be treated with available device size matrix;

11. Successful, uncomplicated (without use of a crossing device) antegrade wire crossing of lesion;

12. A patent inflow artery free from significant lesion (=50% stenosis) as confirmed by angiography (treatment of target lesion acceptable after successful treatment of inflow artery lesions); NOTE: Successful inflow artery treatment is defined as attainment of residual diameter stenosis =30% without death or major vascular complication.

13. At least one patent native outflow artery to the ankle, free from significant (=50%) stenosis as confirmed by angiography that has not previously been revascularized (treatment of outflow disease is NOT permitted during the index procedure);

14. Contralateral limb lesion(s) cannot be treated within 2 weeks before and/or planned 30 days after the protocol treatment in order to avoid confounding complications;

15. No other prior vascular interventions within 2 weeks before and/or planned 30 days after the protocol treatment.

Exclusion Criteria:

Patients will be excluded if ANY of the following conditions apply:

1. Pregnant or planning on becoming pregnant or men intending to father children;

2. Life expectancy of <5 years;

3. Patient is currently participating in an investigational drug or other device study or previously enrolled in this study; NOTE: Enrollment in another clinical trial during the follow up period is not allowed.

4. History of hemorrhagic stroke within 3 months;

5. Previous or planned surgical or interventional procedure within 2 weeks before or within 30 days after the index procedure;

6. History of MI, thrombolysis or angina within 2 weeks of enrollment;

7. Rutherford Class 0, 1, 5 or 6;

8. Renal failure or chronic kidney disease with MDRD GFR =30 ml/min per 1.73 m2 (or serum creatinine =2.5 mg/L within 30 days of index procedure or treated with dialysis);

9. Prior vascular surgery of the index limb, with the exception of remote common femoral patch angioplasty separated by at least 2 cm from the target lesion;

10. Inability to take required study medications or allergy to contrast that cannot be adequately managed with pre- and post-procedure medication;

11. Anticipated use of IIb/IIIa inhibitor prior to randomization;

12. Ipsilateral retrograde access;

13. Composite lesion length is >15 cm or there is no normal proximal arterial segment in which duplex flow velocity can be measured;

14. Significant inflow disease. Successful treatment of inflow disease allowed prior to target lesion treatment;

15. Known inadequate distal outflow (>50 % stenosis of distal popliteal and/or all three tibial vessels), or planned future treatment of vascular disease distal to the target lesion;

16. Sudden symptom onset, acute vessel occlusion, or acute or sub-acute thrombus in target vessel;

17. Severe calcification that renders the lesion un-dilatable;

18. Use of adjunctive treatment modalities (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloon, etc.).

Study Design


Intervention

Device:
Lutonix Drug Coated Balloon
Use of the Lutonix Drug Coated Balloon (DCB) for the treatment of stenosis or occlusion of the femoropopliteal arteries.
Standard PTA Balloon
Use of Standard PTA Balloon in the treatment of stenosis or occlusion of the femoropopliteal arteries.

Locations

Country Name City State
United States TriHealth Heart Institute Cincinnati Ohio
United States Mission Cardiovascular Research Institute Fremont California
United States Jackson Heart Clinic/St. Dominic's Hospital Jackson Mississippi
United States Mission Research Institute New Braunfels Texas
United States New York Presbyterian Hospital/Weill Cornell Medical Center New York New York
United States Mercy Hospital Springfield Missouri
United States Holy Name Medical Center Teaneck New Jersey
United States Metro Health Hospital Wyoming Michigan

Sponsors (1)

Lead Sponsor Collaborator
C. R. Bard

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Unanticipated Device- or Drug-Related Serious Adverse Events at 60 Months Post Index Procedure. From index procedure to 60 months Post Index Procedure
Secondary Number of Subjects With Freedom From Death, Index-Limb Amputation, and Target Vessel Revascularization (TVR) at 30 Days Post Index Procedure Number of subjects with Freedom from all-cause death, index limb amputation above the ankle and Target Vessel Revascularization (TVR) (VIVA Safety Endpoint) 30 days post index procedure
Secondary Number of Participants With All-Cause Perioperative (<30 Day) Death, Index Limb Amputation, Index Limb Re-intervention, and Index Limb Related Death at 1,6, 12, 24, 36, 48, and 60 Months Post Index Procedure 1, 6, 12, 24, 36, 48, and 60 months post index procedure (PPI)
Secondary Percentage of Participants With Primary Patency of the Target Lesion at 6, 12, and 24 Months Post Index Procedure Primary Patency is defined as the absence of target lesion restenosis (defined by DUS peak systolic velocity ratio (PSVR) =2.5) and freedom from target lesion revascularization (TLR). 6, 12, and 24 months post index procedure
Secondary Number of Acute Device Success at Time of Index Procedure Device Success was defined as the achievement of successful delivery and deployment of the study device(s) as intended at the intended target lesion, without balloon rupture or inflation/deflation abnormalities and a successful withdrawal of the study system. At time of index procedure
Secondary Number of Participants With Technical and Procedural Success Technical Success is defined as successful access and deployment of the device and visual estimate of =30% diameter residual stenosis during the index procedure without deployment of a bailout stent.
Procedural Success is defined as attainment of =30% residual stenosis in the treatment area by independent core lab analysis without serious adverse events during the index procedure.
At time of index procedure
Secondary Number of Participants With Freedom From Target Lesion Revascularization (TLR) at 6, 12, and 24 Months Post Index Procedure 6, 12, and 24 months post index procedure
Secondary Number of Participants With Alternative Primary Patency at 6, 12, and 24 Months Post Index Procedure Percentage of subjects with Alternative Primary Patency based on alternative definitions of duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) <2.0 and <3.0 at 6, 12, and 24 months post index procedure. DUS PSVR was calculated by dividing the maximum peak systolic velocity (PSV) from the stenosis by the PSV from the nearest segment of normal artery above the site of increase. 6, 12, and 24 months post index procedure
Secondary Improvement in Rutherford Classification Scores at 6, 12, and 24 Months Post Index Procedure Compared to Baseline The endpoint summarizes the change in index-limb Rutherford Classification of participants from baseline through 24 months. Data is presented as shift from baseline Rutherford Classification data using the following categories: 1) Improvement, 2) Same, and 3) Worsened. 6, 12, and 24 months post index procedure
Secondary Change in Resting Ankle Brachial Index (ABI) at 6, 12, and 24 Months Compared to Baseline Mean change from baseline values. The Ankle Brachial Index (ABI) is defined as a ratio of ankle to brachial (upper arm) artery systolic blood pressure and aims at determining how well the blood is flowing in the legs. 6, 12, and 24 months from baseline
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05712395 - The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease N/A
Active, not recruiting NCT04534257 - Prospective Registry to Investigate the Safety and Efficacy of the Treatment With the Selution Sirolimus Drug Coated Balloon in TASC C and D Atheroma-occlusive Infra-Inguinal Disease in Patients With Chronic Limb Threatening Ischemia From Singapore N/A
Recruiting NCT04511234 - Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Completed NCT02554266 - Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon for Treatment of BTK Arteries
Completed NCT03921905 - Peripheral Artery Disease in Patients With Stable Coronary Artery Disease in General Practice: Prevalence, Management and Clinical Outcomes.
Not yet recruiting NCT06369350 - Vitamin B6 on Exercise Pressor Reflex on Leg Ischemia-reperfusion Early Phase 1
Recruiting NCT04545268 - Prehabilitation for Cardiac Surgery in Patients With Reduced Exercise Tolerance N/A
Recruiting NCT02389023 - Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery N/A
Completed NCT02563535 - Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia Phase 4
Completed NCT02539940 - Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment
Completed NCT02542267 - In-Stent Restenosis Post-Approval Study N/A
Completed NCT02522884 - Tack Optimized Balloon Angioplasty Study of the Tack Endovascular Systemâ„¢ in Femoropoliteal Arteries N/A
Completed NCT02145065 - First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r) N/A
Completed NCT02262949 - A Prospective Study of the Bard® LifeStent® Solo Vascular Stent System N/A
Completed NCT02228564 - BARD® Study of LIFESTREAMâ„¢ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease N/A
Completed NCT01743872 - Optical Imaging Measurement of Intravascular Solution Efficacy Trial N/A
Recruiting NCT01424020 - Walking Estimated Limitation Calculated by History - Study 2 Phase 4
Active, not recruiting NCT01597453 - NOR-SYS: The Norwegian Stroke in the Young Study N/A